|Awarded On||February 15, 2023|
|Title||Harnessing Endoplasmic Reticulum Stress to Overcome Resistance to Immunotherapy in Immune-cold Breast Cancer|
|Award Mechanism||Individual Investigator Research Awards for Clinical Translation|
|Institution/Organization||Baylor College of Medicine|
|Principal Investigator/Program Director||Xi Chen|
*Pending contract negotiation
One of the reasons why cancers arise or recur is their ability to evade the immune surveillance. Breakthrough discoveries over the past 3 decades revealed immune checkpoints molecules, such as PD-1, as key mechanism suppressing tumor-killing T cell function and thus enabling cancer evasion from immune surveillance. Immune checkpoint blockade therapy (ICBT), such as PD-1 inhibitor pembrolizumab, can fully awaken the dysfunctional T cells inside the tumors to destroy the constantly changing cancer cells. However, majority of triple-negative breast cancers (TNBC), the most aggressive form of breast cancer, have little or no T cells inside the tumors, a term called immune-cold. These patients ca...